	w	IPC			PATENT	SCOPE	Mo	bile Deutsch Esp	añol Français ⊟⊅	年語 한국어 Portugue	ê s Русский 中文
				3	Search Inter	national and National P	atent Collec	tions			
	WOR	LD INTE	LLECTU	JAL P	ROPERTY	ORGANIZATION					
S	earch	I	Browse		Translate	Options	News	Login	Help		
lom	e IF	P Services	PATE	NTSCO	OPE						
Re	sults	1-100 of 3	88 for <u>Crit</u>	<u>eria:</u> FI	P:(Bharat Bi	iotech International L	imited) Off	<u>ce(s):</u> all Langua	age:EN Stemmin	ig: true	6
		prev	1		next	Page: 1 / 1 Go >					
Re	fine	Search F	P:(Bharat	t Biotec	h Internationa	I Limited)	Search	RSS 🔊 🛒	1		
							Analysis				
<u> </u>		Dub Date	Dees		A 11		P				
50	rt by:	Pub Date	e Desc	View	All	List Length 100	Machine	translation			
No	Ctr				Title		PubDate	Int.Class	Appl.No	Applicant	Inventor
1.	WO	WO/2014 COMPOS PROCESS	/009971 - Itions ff S for pr	NON-A REE FF EPARA	ICOHOLIC VA ROM ANIMAL- ITION THEREC	ACCINE ORIGIN AND DF	16.01.2014	A61K 39/112	PCT/IN2013 /000418	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
inco inin nflu esp	non no nal-ori enza. ionsib	The novel le to invoke	immunog ohol excip processes immunog	enic to pients. A for pu enicity	Also disclosed rification, remo against infecti	is a method for isolation, oval of endotoxin and form ons against Hib and prev	purification a nation of imm ention and tre	nd conjugation of uno-conjugates ha atment thereof.	bacterial capsula ave also been use	r polysaccharide of d to generate novel d	Haemophilus compositions
•	wo	WO/2013,	/168182 -	VACCI		HONS	14.11.2013	A61K 39/295	/000306	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
/ac aria orr	cine c ations binati	ombination in the com ons are dis	is which co bination of closed. Nu	omprise f these ucleic a	e atleast two or antigens have acids encoding	more of the following and been disclosed that is su the antigens, as well as r	tigens: DTap-l itable for con- methods for th	HEV-HepB-HPV s comitant administr neir production an	uitable for admini ation. The metho d use are provide	stration in humans. <i>I</i> ds of preparing the v d.	A number of accine
3.	WO	WO/2013 AND PRC	/160913 - ICESS FC	rotav R Pre	IRUS VACCIN PARING THE S	IE COMPOSITIONS SAME	31.10.2013	A61K 39/15 😰	PCT/IN2013 /000272	BHARAT BIOTECH INTERNATIONAL LIMITED	VADREVU, Krishna Mohar
nve /acc	ntion cine c cine c	provides ro omposition: composition	tavirus vao s to neutra s with buff	ccine c lize the iers of t	ompositions co high acidic pl the invention a	omprising rotavirus antige H of the stomach without, re stable liquid rotavirus v	ns, stabilizers requiring sep accine formu	and buffers. The parate administrati lations for oral ad	buffers in the inv on of an antacid ministration.	ention are pre-mixed before vaccine admi	in the rotavirus nistration.
ŧ.	US	20130280	293 - COM	MBINAT	TION HEPTAVA	ALENT VACCINE	24.10.2013	A61K 39/295@	13978397	Kuppuswamy Gopinathan	Kuppuswamy Gopinathan
The <i>nflu</i> or a The	inven lenza, a bival prese	tion provide Hepatitis E lent immund ent inventior	es a stable 3, <i>Corynel</i> ogenic cor 1 also relat	immun bacteriu npositic tes to th	nogenic compo um diphtheriae on against rota ne production a	sition for prevention and c, Clostridium tetani, Boru virus and polio virus. The and use of such vaccines	prophylaxis o datella pertus e process of r for prophyla:	f infections cause is (acellular) in a naking such comp is against the infe	d by rota virus, p single combined positions of the m actions mentioned	oliomyelitis virus, Ha vaccine. The inventio ultivalent antigens ard I above.	<i>emophilius</i> on also provides e also disclosed.
í.	US	20130272	999 - Epic	dermal	growth factor o	compositions	17.10.2013	A61K 38/18 💿	13912103	Ella Krishna Murthy	Ella Krishna Murthy
۱ cc ۱cce	ompos eptabl onally	ition for tre e agent, wh pH regulati	eating a wo nerein the ng agent a	ound, w physiol and hur	herein the con logically accep nectant.	nposition can comprise th table agent comprises at	erapeutically least one of a	effective amount a stabilizer, a pres	of an epidermal g ervative, a thicker	rowth factor and a p ning agent, carrier/d	hysiologically luent, and
-	JP	20135272 物	29 - 局所:	適用の	ための新規な	的医薬組成	27.06.2013	A61K 45/06 💿	2013513041	バハラ バイオ テック インター ナショナル リミ テッド	ヴァドレヴ ク リシュナ モハ ン
創乗 質子 あ勿 有を	第二、5000日間 第二、5000日間 第二、5000日間	傷組換、乗。及る 創成え前作前びた に記りにしための新りに に の新りに	直 皮 片 、 は 殖 退 れ た ス 2 1 1 1 1 1 1 1 1 1 1 1 1 1	辱2 日 春 以 子 菌 え に し り で い ち い で い ち い ち い ち い ち い ち い う あ れ し く 、 朝 れ し い う 、 朝 え し 、 い う 、 、 い う 、 、 い う 、 、 い う い う 、 、 い う い い い い い い い い い い い い い	び糖尿病性足 の殺菌薬及び Bharat Biotec は、広域抗生 より広範 より広範 な創 傷治 新 記 新 記 新	部潰瘍の予防及び治療 静菌薬と併用してマイ h International Limited 物質スルファジアジン 剤は、基剤成分、担体 菌薬適用範囲、rh-E 癒等の相乗効果をもた 規な製剤は、保存期間	用の局所製き トジェニック 土のrh-E 銀 (SSD) & 保存剤、等 CGFによる らす。前記 新より長く、	 引の調製のための クタンパク質を含 GF)及び/又 及びクロルへジレイ L(化剤、皮膚軟(S S Dの銀物は、 貯蔵温度2-8 	D新規な相乗作F なな なな た テ シジングルコン ご 和 及び無痛 相 の 逆転、 熟 傷 し ク リ こ 2 で 2 2 の び た 2 の で た 2 の 2 の た 2 の た 2 の た 2 の た 3 で た - 2 の た 5 2 の た 5 2 の た 5 2 の た 5 2 の た 5 2 の た 5 2 の た 5 2 の た 5 5 2 の た 5 5 2 の た 5 5 5 2 の た 5 5 5 2 の た 5 5 5 5 5 5 5 5 5 5 5 5 5	H的医薬組成物が開 3けるマイトジェニ →BBのような任う >酸塩(glucomate) 引並びに1又は2 傷における銀門性 ブル剤又は液剤の飛 えて安定性がある。	 小される。相 ・ックタンパク ⑤の他の成長医 (CHG)で 上の他の構成 微生物に対する 診能で局所製剤

So	rt by:	Pub Date Desc	View	All	List Length 100	Machine	translation			
No	Ctr			Title		PubDate	Int.Class	Appl.No	Applicant	Inventor
7.	EP	2575861 - A NOVE COMPOSITION FO	el syne Dr topi	ERGISTIC PH CAL APPLIC	ARMACEUTICAL ATIONS	10.04.2013	A61K 38/18 💿	10782721	BHARAT BIOTECH INT LTD	VADREVU KRISHNA MOHAN
A no ulce bact and chlo emu cove The stab	ovel sy rs and eriost /or ar rhexic lsifier erage, novel le for	nergistic pharmace d diabetic foot ulcer: atic agents. The mit y other growth fact line glucomate (CH s, skin. emollients a reversal of silver ef composition may b more than two year	eutical co s is disc ogenic p or like rh G). The f nd sooth fect of S e used to s at the s	omposition for losed. The sy protein in the h-PDGF-BB a opical formul lers and one SD by rh-EC o prepare the storage tempo	preparation of topical forr nergistic composition com invention is Recombinant H nd the bactericidal and ba ations, in addition to the sy or more other constituents. F, effectiveness against si topical formulations in the erature of 2-8° degrees.	nulations for p prises a mitog luman Epider cteriostatic ag nergistic com . The novel co lver resistant form of crear	prophylaxis and tr genic protein in co mal Growth Facto gents are broad sg nposition, also cor mposition results microorganisms in n, gel or liquid. Th	eatment of wounds ombination with one rr (rh-EGF of Bhar pectrum antibiotics nprise base ingred in synergistic effer n burn wounds, and ne novel formulation	, burn wounds, skir e or more bactericio at Biotech Interna silver sulfadiazine ients, carriers, pre- cts like broader ant d better and faster ns have longer shel	n grafts, pressure dal and tional Limited) (SSD) and servatives, biacterial wound healing. f life and are
3.	US	20130085103 - NC COMPOSITION FC	OVEL SY DR TOPI	NERGISTIC	PHARMACEUTICAL ATIONS	04.04.2013	A61K 38/18 😰	13701066	Mohan Vadrevu Krishna	Mohan Vadrevu Krishna
A sy pres more Biot inac	nergi sure e inac ech li tive in	stic pharmaceutical ulcers, diabetic foot tive ingredients. The nternational Limite igredients may com	compos ulcers a e synerg ed) and/o prise ca	ition for the p and other skin jistically activ or Platelet De rriers, preser	reparation of topical formu diseases is provided. The e ingredients may include rived Growth Factor (rh-PE vatives, emulsifiers, skin er	lations for us composition Recombinant DGF-BB), silve mollients and	e in prophylaxis a may include one Human Epiderma er sulfadiazine (S soothers and one	nd treatment of wo or more synergistic I Growth Factor (rh SD) and chlorhexic or more other con	unds, burn wounds cally active ingredie n-EGF) (REGEN-D ¹ line gluconate (CH6 stituents.	, skin grafts, ents and one or ™ of Bharat G). One or more
).	CN	102939097 - 用于	局部应用	的新的协同	药物组合物	20.02.2013	A61K 38/18 💿	201080067208.5	巴拉特生物技术 国际有限公司	克修拉·莫汉·威 德麦都
杀长体抗温	剂和 子 防腐 (微生 :下稳)	抑菌剂组合的促细射 如rh-PDGF-BB,并 剂、乳化剂、润肤剂 物的效力、以及更刻 定超过两年。	包分裂蛋 且杀菌剂 利和柔肤 子且更快	白。本发明中 可和抑菌剂是 剂以及一种或 的伤口愈合。	■的促细胞分裂蛋白是重组 广谱抗生素磺胺嘧啶银(SS 这多种其他组分。新组合物 新组合物可用于制备用于	人表皮生长因 SD)和葡萄糖酮 产生协同效应 乳膏、凝胶或	3子(Bharat Biote 睃氛己定(CHG)。 立,如更广的抗菌 就液体形式的局部	ech International I 除了协同组合物以 覆盖、通过rh-EGF 制剂。新制剂具有	.imited的rh-EGF)利 外,局部制剂还包 逆转SSD的银效应 更长的贮存期限并	印/或任何其他生 括基底成分、载 、对抗烧伤中银 且在2-8℃的贮存
0.	WO	W O/2012/172574 INACTIVATED CH	- VACCI IKUNGU	NE COMPOS	SITION COMPRISING AN STRAIN	20.12.2012	A61K 39/12 💿	PCT/IN2012 /000432	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
A va varia expr orote Aedi	ccine ants o essec ective is aeg	composition for pro f the Chikungunya v l as Virus Like Pario against any genoty ypti	ophylaxis irus. Mo cles whic pic varia	s and treatme ore particularly th for use as unts of the Ch	nt of Chikungunya virus in y the invention discloses pa a vaccine antigens agains ikungunya virus which may	fections is dis articular nucle t Chikungunya y be propagat	closed which is c cotide sequences a virus infections. led by any suitabl	apable of conferrir and their translated The compositions e vector of the dise	ng immunity against d proteins thereof, v disclosed in this inv ease including Aedi	any genotypic which may be vention are also s albopictus and
1.	BR	PI0610704 - COM EPIDÉRMICO, O I	POSIÇÃ PROCES	O DO FATOF SSO PARA IS	DE CRESCIMENTO SO E SUA APLICAÇÃO	30.10.2012	A61K 9/00 😰	PI0610704	Bharat Biotech International Limited	
CON onde ager ager	APOS e a co nte fis nte ree	IÇÃO DO FATOR D mposição pode abr iologicamente aceit gulador de PH e um	E CRES anger qu ável abra lectante.	CIMENTO EF Jantidade tera ange, no míni	PIDÉRMICO, O PROCESS apeuticamente eficaz de un mo, um estabilizador, um o	60 PARA ISS m fator de cre conservante, u	O E SUA APLICA escimento epidérn um agente de esp	ÇÃO. Uma compo nico e um agente fi essamento, transp	sição para tratamen isiologicamente ace ortador/diluente e, o	nto de uma ferida eitável, onde o opcionalmente,
2.	BR	PI0711608 - COM VIRAL, MÉTODO I VÍRUS ASSOCIAE DE UMA LINHAGE	POSIÇÃ DE TRA DO, MÉT EM CELL	o liofilizai Tamento ol 'Odo de adj Jlar adeql	DA, USO DE ANTÍGENO I PREVENÇÃO DE APTAÇÃO DE UM VÍRUS JADA	14.08.2012	A61K 39/15 💿	PI0711608	Bharat Biotech International Limited	
CON DE I prote iral iral efer adap de v	/IPOS JM VÍ eína e preen , de u re-se otar u acina o meio	IÇAO LIOFILIZADA IRUS DE UMA LINI- e uma segunda prote ide um açúcar primi- ma primeira proteín a um método de tra m vírus a uma linha is de rotavírus estáv o apropriado em hu	I, USO E IAGEM (eína. Op ário e pe la e de u tamento gem celu veis, viva mano.	DE ANTIGENO CELULAR AD cionalmente, elo menos um ima segunda ou prevenção ular apropriac s/inatívadas,	O VIRAL, METODO DE TR. EQUADA. A presente inve a composição igualmente , preferivelmente dois açúu proteína para a fabricaçãa o do vírus associado a doe la. A invenção é igualment monovalentes e/ou polivale	ATAMENTO C enção refere-s compreende cares secund o de uma com enças nos hur e útil para a p entes, líquidas	DU PREVENÇÃO se a uma composi três díssacarideo ários. A presente posição, preferiv nanos. Além disso rodução de susp v/liofílizadas para	DE VÍRUS ASSOC ição compreenden s diferentes, ou, op invenção igualmer elmente uma vacin. o, a presente inven ensões de vírus ap meio de administra	CIADO, METODO D do um antígeno vira ocionalmente, a con tte refere-se ao uso a. A presente inven ção refere-se a um ropriadas para faza ação oral e/ou nasa	E ADAPTAÇÃO al, uma primeira mposição o de um antígeno ção, além disso, n método de er composições I ou qualquer
3.	WO	WO/2012/093406	- A CON	IBINATION H	EPTAVALENT VACCINE	12.07.2012	A61K 39/04 🔞	PCT/IN2012 /000005	BHARAT BIOTECH INTERNATIONAL LIMITED	KUPPUSWAMY Gopinathan
The nflu a biv ores	inven enza, valent ent in	tion provides a stabl Hepatitis B, Coryne immunogenic comp vention also relates	le immur ebacterit osition a to the pr	nogenic comp um diphtheria against rota vi roduction and	osition for prevention and e, Clostridium tetani, Borda rus and polio virus. The pr use of such vaccines for	prophylaxis o atella pertusis ocess of mak prophylaxis a	f infections cause (acellular) in a si ing such composi gainst the infectio	ed by rota virus, po ngle combined vac tions of the multiva ns mentioned abov	liomyelitis virus, Ha cine. The invention lent antigens are al e	emophilius also provides for so disclosed. The
14.	WO	WO/2012/073257 PROPHYLAXIS AI INFECTIONS IN M	- Vacci Nd tre <i>i</i> Iammal	NE FORMUL ATMENT OF (S	ation for Chandipura Virus	07.06.2012	A61K 39/12 😰	PCT/IN2011 /000817	Bharat Biotech International Limited	ELLA, Krishna Murthy

Sc	ort by:	Pub Date Desc	View All	List Length 100	Machine	e translation					
No	Ctr		Title		PubDate	Int.Class	Appl.No	Applicant	Inventor		
The othe prot puri con and prej	prese er mar eins a fied ir positi elicit paratio	ent invention is relate nmalian hosts. The i und purified from ho nactivated Chandipu ons have been form protective immune r on will also find use	ed to pharmaceutical for immunogenic formulatior st cells. Vaccine compos ira virus in a stable formulated with adjuvants to response in mammalian l in diagnosing for the pre	mulations capable of eli- n comprises Chandipura sitions comprising the re- ulation. Methods of inac potentiate the immune re- host. The immunogenic esence of the virus	citing protecti a virus glycop ecombinant pr tivating Chand esponse. The compositions	ve immune respor rotein (G protein) roteins elicit neutra dipura virus for us vaccine composit are formulated fo	nse against Chandi and/or nucleoprote alizing antibodies s le as a candidate w tions disclosed in th r in vivo administra	pura virus infection in expressed as re- imilar to the vaccine accine are disclose to invention are hig tion to humans. The	in humans and combinant e compositions of d. The vaccine hly immunogenic e immunogenic		
15.	WO	WO/2011/151835 PHARMACEUTIC/ APPLICATIONS	O/2011/151835 - A NOVEL SYNERGISTIC 4ARMACEUTICAL COMPOSITION FOR TOPICAL08.12.2011A61K 38/18 (a)PCT/IN2010 /000468BHARAT BIOTECH INTERNATI LIMITED								
A ne ulce bac and chic emu cow The stat	A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.										
16.	CA	2800417 - A PHAN APPLICATION CC COMBINATION W BACTERIOSTATIC	RMACEUTICAL COMPO OMPRISING A MITOGEN ITH ONE OR MORE BA CAGENTS	SITION FOR TOPICAL IIC AGENT IN CTERICIDAL AND	08.12.2011	A61K 38/18 😰	2800417	BHARAT BIOTECH INTERNATIONAL LIMITED			
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.											
17.	BR	PI0613026 - COMPOSIÇÃO, FRAGMENTO DE NUCLEOTÍDEO, CONSTRUCTO DE DNA RECOMBINANTE, MÉTODO PARA 21.11.2011 A61K 39/085 PI0613026 PRODUZIR PROTEÍNA, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA USO DA MESMA, FORMULAÇÃO, MÉTODO DE ADMINISTRAR COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE PREVENÇÃO E CONTROLE DE INFECÇÕES A61K 39/085 PI0613026							Kandaswamy Sumathy		
COI FAF PRE de v DN/	MPOS RMACI EVEN vacina A recc	IÇÃO, FRAGMENT ÊUTICA E MÉTODO ÇÃO E CONTROLE de polipetídeo para ombinante.	O DE NUCLEOTÍDEO, C O PAPA USO DA MESM DE INFECÇÕES ASSO a prevenção e controle d	CONSTRUCTO DE DNA A, FORMULAÇÃO, MÉT CIADAS A STAPHYLO le infecções mediadas p	RECOMBINA ODO DE ADI COCCUS. A p por Staphyloc	ANTE, MÉTODO F MINISTRAR COM oresente invenção occus em humano	PARA PRODUZIR P POSIÇÃO FARMA(o descreve método os, bovinos e outro	ROTEÍNA, COMPC CÊUTICA, MÉTODO de preparação e us s mamíferos, usano	OSIÇÃO O DE so de formulação do tecnologia de		
18.	IL	209806 - VACCIN HEPATITIS B INFE THE SAME	E COMPOSITION USEF ECTIONS AND A METHO	UL FOR HPV AND DD FOR PREPARING	28.02.2011	A61K / 😰	209806	BHARAT BIOTECH INTERNATIONAL LIMITED			
19.	WO	WO/2011/007363 VACCINE AND A	- A COMPOSITION USE METHOD THEREFOR.	FUL AS ROTAVIRUS	20.01.2011	A61K 39/15 🔞	PCT/IN2010 /000041	BHARAT BIOTECH INTERNATIONAL LIMITED	VADREVU, Krishna, Mohan		
Cor exh	nposit bit be	ions and methods re tter stability charact	elated to live or live attenu eristics and are useful fo	uated pre-conditioned a or the prevention of a ro	nd typical viru tavirus infecti	uses such as rotav on and/or rotaviru	viruses are disclose Is gastroenteritis in	ed. The live attenuat children.	ed rotaviruses		
20.	WO	WO/2010/143194 MULTIPLE CYSTE AND COMPOSITIO	- Stable immunogen Eines Molecules Pro On Thereof	IIC PROTEIN HAVING OCESS THEREFOR	16.12.2010	C07K 14/445@	PCT/IN2009 /000417	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy		
The thar E.c. indu inclue by s of the form suc QS-	The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host E.coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rPvRII and/or rPfF2 to produce cells in high density; inducing expression rPvRII and/or rPfF2 as inclusion bodies; harvesting the cells and isolating the said inclusion bodies; separating rPvRII and/or rPfF2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guandine hydrochloride and / or urea; purifying the protein by subjecting to metal-chelate affinity chromatography; re-folding of the purified rPvRII and/or rPfF2 obtained in step e) with a redox system to recover a high yield of the soluble protein, followed by further purifying the desired protein by removing impurities by subjecting to chromatography. Further the invention discloses formulation comprising rPvRII or rPfF2, preferably being lyophilized using polysaccharides preferably sucrose, lactose, and pharmaceutically acceptable adjuvants such as aluminum hydroxide, aluminum phosphate, CpG nucleotides, non-CpG nucleotides, Montanide ISA-720, MF-59, Mono- phosphoryl Lipid-A (MPL-A) and OS-21.										
21.	US	20100173842 - VA INFECTIONS	ACCINE FOR STAPHYLO	DCOCCAL	08.07.2010	A61K 38/16 😰	12575667	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA Krishna Murthy		

Sor	t by:	Pub Date Desc	View All	List Length 100	Machine	translation			
No	Ctr		Title		PubDate	Int.Class	Appl.No	Applicant	Inventor
The i huma	nven an, bo	tion relates to a met ovine and other mar	hod of preparation and us nmals, using recombinant	e of a polypeptide vac DNA technology.	cine formulat	ion for prevention	and control of Sta	ohylococci mediate	d infections in
22.	US	20100015123 - NO PROCESS THERE	OVEL THROMBOLYTIC MO FOR	DLECULES AND A	21.01.2010	A61K 38/43 💿	12300150	Bharat Biotech International Limited	Ella Krishna Murthy
New varia sequ trans barri wher	thron nts th ence ducti er an usee	nbolytic protein mole nereof, for targeting comprising a stron on domain is useful d find their use in t d a as a therapeutic	ecules such as recombina to brain tissue or any othe g amphipathic alpha helix for enhanced uptake of s he treatment of vascular th . The design and process	nt staphylokinase or s er tissue by either fusi containing protein trar uch protein thromboly rombosis including ce es for cloning, expres	treptokinase, ng to, or by s isduction don tic molecule(s rebrovascular sion, purificat	urokinase, tissue ynthesizing the ca hain. Thrombolytic across the cell r disorders cause ion and protein tra	plasminogen activa andidate thromboly protein molecule(s nembranes and tis d by cerebral thron ansduction of such	ator and the like, an tic molecule(s) with s) so engineered wi sues including the to abosis or cerebral h proteins across ce	d suitable a protein th the protein blood brain aemorrhage Il membranes.
23.	wo	WO/2010/001409 HPV AND HEPATI PREPARING THE	- VACCINE COMPOSITIC TIS B INFECTIONS AND SAME	ON USEFUL FOR A METHOD FOR	07.01.2010	A61K 39/12 🔞	PCT/IN2009 /000333	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
The i mmu	nven inoge	tion describes a vac enicity useful for He	ccine compositions compri patitis B virus as well as h	ising chimeric fusions uman papillomavirus (of the HPV a HPV) infectio	ntigens with viral ons.	or bacterial protein	s conferring enhand	ced
24.	US	20090220538 - VA INFECTIONS	CCINE FOR STAPHYLOC	COCCAL	03.09.2009	A61K 39/085@	12067458	BHARAT BIOTECH INTERNATIONAL LIMITED	Ella Krishna Murthy
n hu 25.	man, MX	MX/a/2008/01439	ammals, using recombina	FUL AS A VACCINE	13.05.2009	A61K 39/15 2	MX/a/2008 /014391	BHARAT BIOTECH INTERNATIONAL	ELLA, Krishna Murthy
elate urth a viru polyv	ermo ermo us to valent	the use of a viral ar re relates to a meth a suitable cell-line. , liquid/lyophilized r	opuonally, the composition titgen, a first protein and a od of treatment or preventi The invention is also usefu otavirus vaccine compositi	a second protein for th on of virus associates all for the production of ions for oral and/or na	e manufacture diseases in h virus suspen Isal or any oth	e of a composition numans. Moreove sions suitable for ner suitable route	n, preferably a vac r, the present inven making stable, live/ of administration in	cine. The present ir tion relates to a me inactivated, monova human.	ivention also ivention thod of adapting alent and/or
26.	US	20080311216 - Me growth factor form	ethods for treating a wound ulation	d using epidermal	18.12.2008	A61K 38/18 😰	11915727	Ella Krishna Murthy	Ella Krishna Murthy
A co acce optio	mpos ptabl nally	ition for treating a v e agent, wherein the pH regulating agen	vound, wherein the compo e physiologically acceptab t and humectant.	sition can comprise the agent comprises at	nerapeutically least one of a	effective amount a stabilizer, a pres	of an epidermal gr ervative, a thickeni	owth factor and a p ng agent, carrier/di	hysiologically luent, and
27.	wo	W O/2008/026225 INFECTION	- A VACCINE FOR CHIKU	JNGUNYA VIRUS	06.03.2008	A61K 39/12 🔞	PCT/IN2007 /000383	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna, Murthy
The provident of the pr	orese malia e viru unoge mbina ence	ent invention relates in hosts. The immur is are discussed. The enic composition is ant viral proteins as of the virus.	to vaccine formulation cap logenic formulation compr le inactivated virus formula formulated for in vivo admi antigens for immunization	able of eliciting prote ises purified inactivate ation is non-infectious inistration to humans. . The recombinant viru	ctive immune ed Chikungun immunogenio The invention us antigens th	response against ya virus in a stabl c and elicits prote also discusses th at are potentially i	Chikungunya virus e formulation. Meth ctive immune respo e strategy of devel mmunogenic can b	infection in human lods of propagation onse in mammalian oping a subunit vac be used in diagnosi	s and other and purification host. The cine using the ng for the
28.	US	20070275006 - IR	IDOID GLYCOSIDE COM	POSITION	29.11.2007	A61K 45/00 🔞	11683975	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Khajuria Anamika
The p actin	orese g as	ent invention relates an adjuvant against	to an adjuvants, particular T-dependent antigen and	ly to the use of a well- specifically against H	characterized BsAg and typ	l plant based irido hoid antigens.	id glycoside adjuva	ant from plant Picro	rhiza kurroa,
ihe j mmu P <i>ich</i> glyco	orese unity. <i>ia pa</i> oside	ent invention also rel The adjuvants may <i>storis</i> , and typhoid adjuvant	ates to the method of proc be used alone or with spe Vi polysaccharide purified	lucing the iridoid glyce cific antigens. The two I from <i>Salmonella typ</i>	oside adjuvan o antigens use hi broth. Thes	t and the products ed in the study rep e antigens are stu	: utilizing such adju presents HBsAg, a idied for their immu	vants tor induction recombinant antige unogenicity with the	ot cellular n expressed in adjuvant iridoid
29.	wo	WO/2007/132480	- A COMPOSITION USEF	UL AS A VACCINE	22.11.2007	A61K 39/15 💿	PCT/IN2007 /000190	BHARAT BIOTECH INTERNATIONAL	ELLA, Krishna, Murthy

No	rt by:	Pub Date Desc	View	All	List Length 100	Machine	translation			
NO	Ctr			Title		PubDate	Int.Class	Appl.No	Applicant	Inventor
									LIMITED	
The diffe elate urth a vir poly	prese erent c tes to nermo rus to valent	nt invention relates lisaccharaides, or, the use of a viral ar re relates to a meth a suitable cell-line. , liquid/lyophilized r	to a con optionall tigen, a od of tre The inve otavirus	nposition compris y, the compositio first protein and atment or preven ntion is also usef vaccine composi	sing a viral antigen, a fi n comprises a primary a second protein for th tion of virus associates ul for the production of tions for oral and/or na	rst protein and sugar and at e manufacture diseases in h virus suspen asal or any oth	d a second protein least one, prefera e of a composition numans. Moreover sions suitable for her suitable route	n. Optionally, the c bly two secondary , preferably a vac , the present inver making stable, live of administration ir	omposition also con sugars. The present cine. The present ir tition relates to a me /inactivated, monova human.	nprises three nt invention also nvention thod of adaptin alent and/or
30.	WO	WO/2007/132481 A PROCESS THE	- NOVE REFOR	L THROMBOLYT	IC MOLECULES AND	22.11.2007	C07K 14/31 @	PCT/IN2007 /000191	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
The and thror mole and thror prote	inven the lik mboly cule(tissue mbosi ein tra	tion discloses a new ke, and is suitable to tic molecule(s) with s) so engineered wi so including the bloc s or cerebral haem ansduction of such p	v THROM their va a protei th the pr d brain prrhage proteins	/BOLYTIC protei triants thereof, fo n sequence com rotein transductio barrier and find t when used a as across cell memb	n molecules such as re r targeting to brain tiss prising a strong amphi n domain is useful for heir use in the treatme a therapeutic. The inve pranes.	ecombinant sta ue or any oth pathic alpha h enhanced upt nt of vascular ntion disclose	aphylokinase or st er tissue by either elix containing pro ake of such prote thrombosis includ s the design and	reptokinase, urokin fusing to, or by sy otein transduction d in thrombolytic mo ing cerebrovascula processes for clon	nase, tissue plasmir nthesizing the can domain. Thrombolyt lecule(s) across the ar disorders caused ing, expression, pur	nogen activator didate ic protein cell membrane I by cerebral ification and
31.	WO	WO/2007/007352 INFECTIONS	- A VAC	CINE FOR STAF	PHYLOCOCCAL	18.01.2007	C07K 14/31 👩	PCT/IN2006 /000246	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
The in hı	prese uman,	ent invention describ bovine and other n	es meth nammals	od of preparatior , using recombin	and use of polypeptic ant DNA technology.	le vaccine for	nulation for preve	ntion and control c	f Staphylococci me	diated infectior
32.	KR	1020060132590 - PURIFICATION OF	a proc F reco	ESS FOR THE F MBINANT PROTE	PREPARATION AND EINS	21.12.2006	C07K 1/14 👩	1020067010166	BHARAT BIOTECH INTERNATIONAL LIMITED	ella Krishn Murthy
		Composition, A Application	PROCE	ESS THEREFOR	AND ITS			/000168	BIOTECH INTERNATIONAL LIMITED	ELLA, Krishn Murthy
A co acce optic	ompos eptabl onally	ition for treating a v e agent, wherein the pH regulating agent	vound, w e physio t and hu	wherein the comp logically accepta mectant.	osition can comprise t ble agent comprises at	nerapeutically least one of a	effective amount a stabilizer, a pres	of an epidermal gr ervative, a thicken	owth factor and a p ing agent, carrier/di	hysiologically luent, and
34.	WO	WO/2006/021965 FORMULATION FO	- EUKAI DR GAS	RYOTIC BASED TRO-INTESTINA	SYNERGISTIC L DISORDERS	02.03.2006	A61K 36/062	PCT/IN2004 /000256	BHARAT BIOTECH INTERNATIONAL LIMITED	ELLA, Krishna Murthy
The phar	prese rmace	ent invention describ eutically and or phys	es a eul iologica	karyotic based sy Ily acceptable co	nergistic formulation f					waruty
soyt and gastr	medit bean o Vitam ro inte	casein dextrose med nins, D-Biotin and th estinal disorders by) them a dium (SC iamine H adminis	nd the method us CDM) for Nitroge ICI ranging from tering in various	mponents. The invention sed to convert the form in source, MgSo4, KCl, 0.001% to 0.6% and c forms to the mammals	or gastro-intes on also descril ulation to disp NaCl, (NH)4H lesignated as including hum	stinal disorders co bes the manner in ensable forms. Th IPO4 and with min BBIL-SB. The for an suffering there	mprising eukaryot which the eukaryot e medium compris proelements like M mulation can be ef from, in a require	ics and adjuncts sel bics are isolated fro sing Glucose for car nSO4, FeSO4, CuS fectively used to pre id quantity.	ected from om tropical fruit bon source, O4, Boric acid event and or cu
soyt and gast	WO	WO/2005/070454) them a dium (SC iamine H adminis - A NOV RATION	nd the method us CDM) for Nitroger HCI ranging from tering in various HCL PROCESS C	mponents. The invention sed to convert the form in source, MgSo4, KCI, 0.001% to 0.6% and co forms to the mammals F HEPATITIS A	or gastro-Intes on also descrii ulation to disp NaCI, (NH)4H lesignated as including hum 04.08.2005	stinal disorders co bes the manner in ensable forms. Th IPO4 and with mid BBIL-SB. The for an suffering there A61K 39/29 @	mprising eukaryot which the eukaryot e medium compris croelements like M mulation can be ef from, in a require PCT/IN2005 /000020	ics and adjuncts sel otics are isolated fro sing Glucose for car nSO4, FeSO4, CuS fectively used to pre- d quantity. BHARAT BIOTECH INTERNATIONAL LIMITED	ected from om tropical fruit bon source, O4, Boric acid event and or cu CHITAMBER, Shobha, Dattatraya
An Information of the provided	Mediu Dean o Vitam ro inte WO Ndian vaccin be viru Daratio	WO/2005/070454 VACCINE PREPA isolate of Hepatitis is and further adapt on of an inactivated) them a dium (SC iamine I adminis - A NOV RATION A virus- method ation to ' vaccine.	nd the method us DDM) for Nitrogei -CI ranging from tering in various /EL PROCESS C NIVIN97 has bee involves the cell of Vero and MRC-5	mponents. The invention end to convert the form in source, MgSo4, KCI, 0.001% to 0.6% and co forms to the mammals OF HEPATITIS A en isolated, adapted to ulture adaptation of the cells, scale-up, inactiv	tissue culture e virus isolate vation and dow	stinal disorders cc oes the manner. In ensable forms. In PPO4 and with mid BBIL-SB. The for an suffering there A61K 39/29 (2) characterized ar from clinical sam yn stream process	mprising eukaryot which the eukaryo e medium compris croelements like M mulation can be ef from, in a require PCT/IN2005 /000020 nd further propagat ole (faecal) in BGM sing method of the	ics and adjuncts sel otics are isolated fro sing Glucose for car nSO4, FeSO4, CuS fectively used to pre- id quantity. BHARAT BIOTECH INTERNATIONAL LIMITED ted using Vero and IK cell line initially , inactivated viral ant	CHITAMBER, Shobha, Dattatraya MRC-5 cell line characterizatic igens for the
An In for v of th orep 36.	mediu pean o Vitam ro inte WO ndian vaccin ae viru paratic	WO/2005/070454 VACCINE PREPA isolate of Hepatitis e preparation. The s and further adapt on of an inactivated WO/2005/063794 PURIFICATION OF	a them a dium (SC iamine I adminis - A NOV RATION A virus- method ation to ' vaccine. - A PRC - RECO	nd the method us DM) for Nitrogen HCI ranging from tering in various //EL PROCESS C NIVIN97 has been involves the cell of Vero and MRC-5 	mponents. The invention end to convert the form in source, MgSo4, KCI, 0.001% to 0.6% and of forms to the mammals F HEPATITIS A en isolated, adapted to sulture adaptation of the cells , scale-up ,inaction PREPARATION AND EINS	on also descril nalso descril ulation to disp NaCI, (NH)4Hesignated as including hum 04.08.2005 tissue culture e virus isolate vation and dow 14.07.2005	stinal disorders oc pos the manner in ensable forms. Th IPO4 and with mid BBIL-SB. The for an suffering there A61K 39/29 , characterized ar from clinical sam yn stream process C07K 1/36 2	mprising eukaryot which the eukaryot e medium compris croelements like M mulation can be ef from, in a require PCT/IN2005 /000020 nd further propagat ble (faecal) in BGN sing method of the PCT/IN2004 /000257	ics and adjuncts sel otics are isolated fro sing Glucose for car nSO4, FeSO4, CuS fectively used to pre- id quantity. BHARAT BIOTECH INTERNATIONAL LIMITED BHARAT BIOTECH INTERNATIONAL LIMITED	ected from om tropical fruit bon source, O4, Boric acid event and or cu CHITAMBER, Shobha, Dattatraya MRC-5 cell line characterizatio igens for the ELLA, Krishn Murthy
An In For v of thorep 36. A no oy h appli	wediu Vitam wo wo ndian accin accin accin wo wo wo wo wo vel pr nydrop icatio	WO/2005/070454 VACCINE PREPA isolate of Hepatitis le preparation. The s and further adapt on of an inactivated WO/2005/063794 PURIFICATION Of rocess for the purific phobic interaction. The in vaccines and p	a them a dium (SC iamine I adminis - A NOV RATION A virus- method ation to ' vaccine. - A PRC - A PRC - RECO	nd the method us DM) for Nitrogei HCI ranging from tering in various /EL PROCESS C NIVIN97 has been involves the cell of Vero and MRC-5 CESS FOR THE MBINANT PROTE for recombinant pro- action of this pro- puticals.	mponents. The invention end to convert the form in source, MgSo4, KCI, 0.001% to 0.6% and of forms to the mammals OF HEPATITIS A en isolated, adapted to julture adaptation of the cells , scale-up ,inaction PREPARATION AND EINS Detein expressed as profile tein step resulted in an	or gastro-intee on also descril ulation to disp NaCl, (NH)4H lesignated as including hum 04.08.2005 tissue culture e virus isolate vation and dow 14.07.2005 ein or particle increase in re	stinal disorders oc pes the manner in ensable forms. Th HPO4 and with mid BBIL-SB. The for an suffering there A61K 39/29 characterized ar from clinical samp vn stream process C07K 1/36 is herewith desc accovery and purity	mprising eukaryot which the eukaryot e medium compris croelements like M mulation can be ef from, in a require PCT/IN2005 /000020 nd further propagat ble (faecal) in BGM sing method of the PCT/IN2004 /000257	ics and adjuncts sel offics are isolated fro sing Glucose for car nSO4, FeSO4, CuS fectively used to pre- id quantity. BHARAT BIOTECH INTERNATIONAL LIMITED ted using Vero and IK cell line initially , inactivated viral ant BHARAT BIOTECH INTERNATIONAL LIMITED cation process, the The protein further pro-	ected from om tropical fruit bon source, O4, Boric acid event and or cu CHITAMBER, Shobha, Dattatraya MRC-5 cell line characterizatic igens for the ELLA, Krishna Murthy protein is purifi

Sc	ort by:	Pub Date Desc	View	All	List Length 100	Machine	translation				
No	Ctr			Title		PubDate	Int.Class	Appl.No	Applicant	Inventor	
A no by h app	A novel process for the purification of recombinant protein expressed as protein or particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.										
38.	US	6897041 - Express	sion of r	ecombinant matur	re lysostaphin	24.05.2005	C12N 9/52 😰	10110795	Bharat Biotech International Limited	Khatri Ghan Shyam	
A portion of the lysostaphin gene of <i>Staphylococcus simulans</i> has been cloned and overexpressed in the cytoplasm of <i>E. coli</i> to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent <i>staphylococcal</i> infections.											
Re	sults	1-100 of 38 for <u>Cr</u> prev 1 Search FP:(Bhara	<u>iteria:</u> F	P:(Bharat Biotone Bio	ech International L	imited)Offi Search	<u>ce(s):</u> all <u>Langua</u>	age:EN <u>Stemmino</u>	<u>g:</u> true		